XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Astellas Gene Therapies, Inc. (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2024
USD ($)
target
indication
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues   $ 18,306,000 $ 356,000 $ 24,743,000 $ 837,000
Deferred revenues $ 7,556,000 7,556,000   7,556,000  
Deferred revenues, non-current $ 5,874,000 5,874,000   5,874,000  
Astellas Gene Therapies, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Royalty obligation, term 10 years        
License | Astellas Gene Therapies, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Number of additional targets | target 4        
Number of indications per target | indication 3        
Agreement term 3 years        
Contract with customer liability $ 20,000,000        
Variable consideration amount $ 1,300,000,000        
Number of targets | target 5        
Initial License | Astellas Gene Therapies, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability $ 6,500,000        
Revenues 6,500,000        
Additional Licenses | Astellas Gene Therapies, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability $ 13,500,000 13,500,000   13,500,000  
Revenues   0 $ 0    
Deferred revenues   7,600,000   7,600,000  
Underlying options, exercise or expiration term 4 years        
Deferred revenues, non-current   $ 5,900,000   $ 5,900,000